Skip to content

Study · Not a test of the peptide alone · 2001

3 results

[Nucleic acid and protein content in rat prostate during combined treatment with the gonadorelin agonist and an androgen receptor inhibitor].

Sachyns'ka OV

Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994)1 Jan 2001

PMID11962088 (opens in a new tab)PepBankPUB-11962088
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Gonadorelin (GnRH, LHRH).

  1. 01AnimalNot a test of Gonadorelin (GnRH, LHRH) aloneAnimal study (in vivo)Efficacy outcome

    In male rats, combined treatment with the androgen receptor blocker flutamide and the LH-releasing hormone agonist Surfagon decreased DNA content in the ventral prostate.

    In plain wordsIn male rats, flutamide plus the LH-releasing hormone agonist Surfagon lowered DNA content in the prostate.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    DecreaseProstate DNA content
    Study

    ratn: not reported in source

    ventral prostate of male rats
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    It was shown that combined drug treatment led to potentiating of "antiprostatic" effects of both preparations resulted in significant decrease of DNA, RNA and protein contents.
    1 context sentence
    Summary · context
    The effects of androgen receptor blocker Flutamide (Niftolide) and/or LH-releasing hormone agonist Surfagon on the nucleic acids and protein contents in the ventral prostate of male rats were studied.

    In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).

  2. 02AnimalNot a test of Gonadorelin (GnRH, LHRH) aloneAnimal study (in vivo)Efficacy outcome

    In male rats, combined treatment with flutamide and the LH-releasing hormone agonist Surfagon decreased RNA content in the ventral prostate.

    In plain wordsIn male rats, flutamide plus the LH-releasing hormone agonist Surfagon lowered RNA content in the prostate.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    DecreaseProstate RNA content
    Study

    ratn: not reported in source

    ventral prostate of male rats
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    It was shown that combined drug treatment led to potentiating of "antiprostatic" effects of both preparations resulted in significant decrease of DNA, RNA and protein contents.
    1 context sentence
    Summary · context
    The effects of androgen receptor blocker Flutamide (Niftolide) and/or LH-releasing hormone agonist Surfagon on the nucleic acids and protein contents in the ventral prostate of male rats were studied.

    In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).

  3. 03AnimalNot a test of Gonadorelin (GnRH, LHRH) aloneAnimal study (in vivo)Efficacy outcome

    In male rats, combined treatment with flutamide and the LH-releasing hormone agonist Surfagon decreased protein content in the ventral prostate.

    In plain wordsIn male rats, flutamide plus the LH-releasing hormone agonist Surfagon lowered protein content in the prostate.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    DecreaseProstate protein content
    Study

    ratn: not reported in source

    ventral prostate of male rats
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    It was shown that combined drug treatment led to potentiating of "antiprostatic" effects of both preparations resulted in significant decrease of DNA, RNA and protein contents.
    1 context sentence
    Summary · context
    The effects of androgen receptor blocker Flutamide (Niftolide) and/or LH-releasing hormone agonist Surfagon on the nucleic acids and protein contents in the ventral prostate of male rats were studied.

    In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.